131I-metaiodobenzylguanidine (131I-MIBG) is a norepinephrine analog that concentrates in adrenergic tissue and therefore holds promise for cell-specific treatment of neuroblastoma. This is a dual institution, Phase II study of 131I-MIBG administered at the previously defined maximum practical dose of 18 mCi/kg to children with relapsed or refractory neuroblastoma.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.